Does Lacosamide Cause Irregular Heartbeats?
Yes, lacosamide (Vimpat) can cause irregular heartbeats, primarily through PR interval prolongation, which may lead to atrioventricular (AV) block or other conduction abnormalities. This effect stems from its sodium channel-blocking action, slowing cardiac conduction. Clinical trials reported PR prolongation in up to 9% of patients at higher doses (400-600 mg/day), with second- or third-degree AV block in rare cases (0.2-0.5%).[1][2]
How Common Is This Side Effect?
Irregular heartbeats occur in 1-10% of users, depending on dose and patient factors. Post-marketing data shows higher risks in those with pre-existing heart conditions, including bradycardia (slow heart rate) in 0.5-1% and atrial fibrillation or flutter in under 1%. ECG monitoring is recommended during initiation or dose increases.[1][3]
Who Is Most at Risk?
Patients with conduction disorders, heart failure, myocardial ischemia, or second-/third-degree AV block face elevated risks—lacosamide is contraindicated in these groups. Elderly patients or those on beta-blockers, calcium channel blockers, or other sodium channel agents (e.g., carbamazepine) may experience additive effects. Baseline ECG and monitoring are advised.[2][4]
What Do Doctors Recommend for Monitoring?
Guidelines from the FDA and EMA call for ECGs before starting and periodically thereafter, especially above 400 mg/day. Dose adjustments or discontinuation may be needed if PR interval exceeds 240 ms or new arrhythmias appear. Symptoms like dizziness, syncope, or palpitations warrant immediate evaluation.[1][3]
Are There Safer Alternatives for Seizure Control?
For patients prone to cardiac issues, alternatives include levetiracetam (Keppra), which lacks cardiac conduction effects, or lamotrigine, with minimal PR prolongation risk. Valproate or topiramate are options but carry other side effects like weight gain or cognitive issues. Choice depends on epilepsy type and comorbidities—consult a neurologist.[4][5]
What Does Real-World Data Show?
VigiBase and FAERS reports link lacosamide to over 1,000 cardiac arrhythmia cases since 2008, with many involving polytherapy. A 2022 study in Epilepsia found 2.4% incidence of significant PR prolongation in 1,500 patients, reversible upon discontinuation. No direct link to sudden cardiac death, but caution persists.[3][6]
[1]: FDA Label for Vimpat (lacosamide)
[2]: EMA Product Information for Vimpat
[3]: Drugs.com - Lacosamide Side Effects
[4]: UpToDate - Lacosamide: Adverse Effects
[5]: Epilepsy Foundation - Antiepileptic Drug Comparisons
[6]: PubMed - Cardiac Effects of Lacosamide (2022 Review)